A historical perspective on the development of the cytarabine (7 days) and daunorubicin (3 days) treatment regimen for acute myelogenous leukemia: 2013 the 40th …
MA Lichtman - Blood Cells, Molecules, and Diseases, 2013 - Elsevier
This paper reviews the development of therapy for acute myelogenous leukemia that in
1973 led to the regimen of 7days of continuous intravenous arabinosylcytosine (cytarabine)
and the first 3 concurrent days of intravenous daunorubicin, given the nickname “7+ 3.” The
state of leukemia treatment in the 1950s, 1960s and early 1970s is reviewed, the discovery
of the two drugs in question described, and the introduction of clinical trials to reach an
optimal regimen for their use delineated. During the 1950s, following World War Two and …
1973 led to the regimen of 7days of continuous intravenous arabinosylcytosine (cytarabine)
and the first 3 concurrent days of intravenous daunorubicin, given the nickname “7+ 3.” The
state of leukemia treatment in the 1950s, 1960s and early 1970s is reviewed, the discovery
of the two drugs in question described, and the introduction of clinical trials to reach an
optimal regimen for their use delineated. During the 1950s, following World War Two and …